73217-31-9

Usage

Uses

Used in Medicinal Chemistry and Pharmaceutical Research:
3-(CHLOROMETHYL)-5-(4-METHOXYPHENYL)-1,2,4-OXADIAZOLE is utilized as a chemical intermediate in the development of new pharmaceuticals, leveraging its biological activities for potential therapeutic applications. Its unique structure allows for the exploration of its interactions with biological targets, which may lead to the discovery of novel treatments for various diseases and conditions.
Used in Organic Synthesis:
In the field of organic synthesis, 3-(CHLOROMETHYL)-5-(4-METHOXYPHENYL)-1,2,4-OXADIAZOLE serves as a building block for the creation of more complex organic compounds. Its presence in these syntheses can contribute to the formation of molecules with specific properties, such as enhanced stability, reactivity, or selectivity, which are desirable in various chemical processes.
Used in Material Science:
3-(CHLOROMETHYL)-5-(4-METHOXYPHENYL)-1,2,4-OXADIAZOLE is also employed in material science as a component in the design and synthesis of new materials. Its incorporation into these materials can impart specific characteristics, such as improved thermal stability, chemical resistance, or mechanical properties, which are valuable in a range of applications, from coatings and adhesives to advanced composites and electronic devices.
Used in Chemical Research:
In the realm of chemical research, 3-(CHLOROMETHYL)-5-(4-METHOXYPHENYL)-1,2,4-OXADIAZOLE is a subject of study for understanding its reactivity, stability, and potential interactions with other chemical entities. This research can provide insights into the compound's behavior under various conditions and contribute to the advancement of chemical knowledge and the development of new technologies.

InChI:InChI=1/C10H9ClN2O2/c1-14-8-4-2-7(3-5-8)10-12-9(6-11)13-15-10/h2-5H,6H2,1H3

Upstream product

• 100-07-2 4-methoxy-benzoyl chloride 
• 255876-60-9 C₁₀H₁₁ClN₂O₃ 

Downstream Products

• 73235-62-8 N'-[5-(4-methoxy-phenyl)-[1,2,4]oxadiazol-3-ylmethylene]-N,N-dimethyl-benzene-1,4-diamine N'-oxide 
• 73217-43-3 1-[5-(4-methoxy-phenyl)-[1,2,4]oxadiazol-3-ylmethyl]-pyridinium; chloride 

Relevant academic research and scientific papers

ALKALOID AMINOESTER DERIVATIVES AND MEDICINAL COMPOSITION THEREOF

The present invention relates to alkaloid aminoester derivatives acting as muscarinic receptor antagonists, processes for their preparation, compositions comprising them and therapeutic uses thereof.

Novel 1,3-dipropyl-8-(1-heteroarylmethyl-1H-pyrazol-4-yl)-xanthine derivatives as high affinity and selective A2B adenosine receptor antagonists

A series of new 1,3-dipropyl-8-(1-heteroarylmethyl-1H-pyrazol-4-yl)- xanthine derivatives as A2B-AdoR antagonists have been synthesized and evaluated for their binding affinities for the A2B, A 1, A2A, and A3-AdoRs. 8-(1-((3-phenyl-1,2,4- oxadiazol-5-yl)methyl)-1H-pyrazol-4-yl)-1,3-dipropyl-1H-purine-2,6(3H,7H)-dione (4) displayed high affinity (Ki = 1 nM) and selectivity for the A2B-AdoR versus A1, A2A, and A 3-AdoRs (A1/A2B, A2A/A2B, and A3/A2B selectivity ratios of 370, 1100, and 480, respectively). The synthesis and SAR of this novel class of compounds are presented herein.

The discovery of a selective, high affinity A2B adenosine receptor antagonist for the potential treatment of asthma

Adenosine has been suggested to play a role in asthma, possibly via activation of A2B adenosine receptors on mast cells and other pulmonary cells. We describe our initial efforts to discover a xanthine based selective A2B AdoR antagonist that resulted in the discovery of CVT-5440, a high affinity A2B AdoR antagonist with good selectivity (A2B AdoR Ki = 50 nM, selectivity A1 > 200: A2A > 200: A3 > 167).

CVT-4325: A potent fatty acid oxidation inhibitor with favorable oral bioavailability

New inhibitors of palmitoyl-CoA oxidation are based on the introduction of nitrogen heterocycles in the 'Western Portion' of the molecule. SAR studies led to the discovery of CVT-4325, a potent FOXi (IC50 = 380 nM, rat mitochondria) with favorable PK properties (F = 93%, t1/2 = 13.6 h, dog). New inhibitors of palmitoyl-CoA oxidation are based on the introduction of nitrogen heterocycles in the 'Western Portion' of the molecule. SAR studies led to the discovery of CVT-4325 (shown), a potent FOXi (IC50 = 380 nM rat mitochondria) with favorable PK properties (F = 93%, t1/2 = 13.6 h, dog).